rethinkPeptides Search
Menu
Study breakdown

How Antimicrobial Peptides Protect the Eye and May Treat Dry Eye Disease

ReviewN/A (Review) evidence
The takeaway

Antimicrobial peptides on the ocular surface play critical roles in fighting infections, healing wounds, and modulating immune responses — and their disruption may contribute to dry eye diseases.

Triple function

AMPs on the eye surface simultaneously fight microbes, heal wounds, and regulate immune responses — disruption of any function may contribute to dry eye

What the researchers found

Antimicrobial peptides on the ocular surface serve multiple functions including microbial defense, wound healing, and immune modulation, and their homeostasis is disrupted in dry eye disease states.

Why it matters

Dry eye affects millions of people and current treatments are limited. Understanding AMPs' protective roles could lead to peptide-based eye drops or therapies that address the root immune dysfunction, not just symptoms.

The numbers in context

AMPs: defensins, cathelicidins; roles: antimicrobial, wound healing, immune modulation; altered in dry eye

How the study worked

Narrative review of published literature on antimicrobial peptides in ocular surface health and dry eye diseases.

Who was studied

Review of AMPs in ocular surface health and dry eye diseases

What this study cannot tell us

Narrative review with no new experimental data. Most AMP research in dry eye is preclinical. Clinical translation of peptide-based eye treatments faces stability and delivery challenges.

How to read the evidence

Not applicable (narrative review). Synthesizes preclinical and observational evidence on AMPs in ocular surface health.

When this study was published

Published in 2021. Research on peptide-based eye therapies continues to advance.

The bigger picture

AMPs are being increasingly recognized for roles beyond simple antimicrobial activity. Their immune-modulatory and wound-healing functions make them promising candidates for treating inflammatory conditions of the eye, potentially replacing or complementing current anti-inflammatory therapies.

Questions still open

  • Could topical AMP formulations effectively treat dry eye disease?
  • Which specific antimicrobial peptides are most altered in dry eye, and do levels correlate with disease severity?
  • Would AMP-based therapies complement or replace current anti-inflammatory dry eye treatments?

Common questions

What do antimicrobial peptides do in the eye?
AMPs on the eye surface act as a first line of defense — killing bacteria and other pathogens, promoting healing when the surface is damaged, and regulating inflammation. When these peptides are disrupted, the eye becomes more vulnerable to infection and inflammatory conditions like dry eye.
Could peptide-based eye drops treat dry eye?
Potentially. Researchers are exploring whether AMPs or AMP-derived molecules could be developed as eye drops to restore the protective functions that are disrupted in dry eye disease. This is still in early research stages.

Read the original research

The Role of Endogenous Antimicrobial Peptides in Modulating Innate Immunity of the Ocular Surface in Dry Eye Diseases.

International journal of molecular sciences, 22(2)

Citation

Eshac, Youssof; Redfern, Rachel L; Aakalu, Vinay Kumar. (2021). The Role of Endogenous Antimicrobial Peptides in Modulating Innate Immunity of the Ocular Surface in Dry Eye Diseases.. International journal of molecular sciences, 22(2). https://doi.org/10.3390/ijms22020721